Armata Pharmaceuticals, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
ARMP
Armata Pharmaceuticals, Inc. Common Stock
$4.68 +2.63%
VS HALOHalozyme Therapeutics, Inc.
$106.57 +1.60%
Armata Pharmaceuticals, Inc. Common Stock and Halozyme Therapeutics, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ARMP | HALO | |
|---|---|---|
| Market Cap | $166.58 million | $11.69 billion |
| Revenue (TTM) | — | $1.66 billion |
| Net Income (TTM) | — | $413.60 million |
HALO leads on 1 of 1 size & scale factors.
Valuation
| ARMP | HALO | |
|---|---|---|
| P/E Ratio | — | 31.16 |
| Price / Book | — | 81.44 |
| Price / Sales | — | 7.03 |
ARMP and HALO split the valuation factors evenly.
Profitability
| ARMP | HALO | |
|---|---|---|
| Net Margin | — | 24.86% |
| Return on Equity | — | 288.13% |
ARMP and HALO split the profitability factors evenly.
Risk & Sentiment
| ARMP | HALO | |
|---|---|---|
| Short Interest | 0.37% | 9.79% |
ARMP leads on 1 of 1 risk & sentiment factors.
Dig deeper: ARMP overview, ARMP financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.